US 11,667,921 B2
Regulation of translation of expressed genes
Raymond Michael Dimphena Verhaert, BG Breda (NL); Pieter Victor Schut, CA Leiden (NL); Sharief Barends, ZN Voorschoten (NL); and Maurice Wilhelmus van der Heijden, GW Gouda (NL)
Assigned to Proteonic Biotechnology IP B.V., Leiden (NL)
Filed by Proteonic Biotechnology IP B.V., Leiden (NL)
Filed on Dec. 28, 2020, as Appl. No. 17/135,500.
Application 17/135,500 is a continuation of application No. 15/720,428, filed on Sep. 29, 2017, granted, now 10,876,113.
Application 15/720,428 is a continuation of application No. 13/877,259, abandoned, previously published as PCT/NL2011/050664, filed on Sep. 30, 2011.
Claims priority of provisional application 61/388,668, filed on Oct. 1, 2010.
Claims priority of application No. 10186102 (EP), filed on Oct. 1, 2010.
Prior Publication US 2021/0115446 A1, Apr. 22, 2021
Int. Cl. C12N 15/113 (2010.01); C12P 21/00 (2006.01); A61K 48/00 (2006.01)
CPC C12N 15/113 (2013.01) [A61K 48/005 (2013.01); C12P 21/00 (2013.01)] 20 Claims
 
1. A nucleic acid molecule comprising a first nucleotide sequence which comprises from its 5′ end to its 3′ end:
i) a TC-rich nucleotide sequence comprising at least 12 consecutive C or T nucleotides,
ii) 4 A-rich nucleotide sequences comprising at least 5 consecutive A nucleotides,
iii) a GT-rich nucleotide sequence comprising at least 12 nucleotides, at least 80% of which are G or T nucleotides, and
iv) a an intron sequence comprising at least splice sites required for splicing of the intron sequence,
wherein the first nucleotide sequence has at least 90% sequence identity with SEQ ID NO: 2.